However, inhibition of ACOX1 expression with 10,12-Tricosadiynoic acid in combination with middle- or low-dose OCA significantly improves steatohepatitis and liver fibrosis, with efficacy comparable to high-dose OCA, but without adverse effects on LDL and HDL levels. Here, ACOX1 is linked to Hepatic fibrosis.